世界のIn Vivo毒性試験市場予測:製品別、試験タイプ別、毒性指標別、試験施設別、エンドユーザー別

MarketsandMarketsが発行した調査報告書(BT6000)
◆英語タイトル:In Vivo Toxicology Market by Product (Animal Models, Reagents & Kits), Test Type (Chronic, Sub-acute), Toxicity Endpoints (Systemic, Immunotoxicity), Testing Facility (Outsourced, In-house), End User (Academic & Research Institute, CROs) - Forecast to 2025
◆商品コード:BT6000
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2021年3月25日
◆ページ数:264
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内
◆調査対象地域:グローバル
◆産業分野:バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥534,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥718,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥880,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。

マーケッツアンドマーケッツ社は、世界のIn Vivo毒性試験市場規模が2020年50億ドルから2025年66億ドルまで、年平均5.5%成長すると予測しています。本調査資料では、In Vivo毒性試験の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(消耗品、器具)分析、試験タイプ別(慢性毒性試験、亜慢性毒性試験、亜急性毒性試験、急性毒性試験)分析、試験施設別(外部委託、機関内)分析、毒性指標別(免疫毒性、全身、発がん性、遺伝毒性、発生毒性&生殖毒性)分析、地域別分析、競争状況、企業情報などを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界のIn Vivo毒性試験市場規模:製品別(消耗品、器具)
・世界のIn Vivo毒性試験市場規模:試験タイプ別(慢性毒性試験、亜慢性毒性試験、亜急性毒性試験、急性毒性試験)
・世界のIn Vivo毒性試験市場規模:試験施設別(外部委託、機関内)
・世界のIn Vivo毒性試験市場規模:毒性指標別(免疫毒性、全身、発がん性、遺伝毒性、発生毒性&生殖毒性)
・世界のIn Vivo毒性試験市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

“The global in vivo toxicology market size is projected to reach USD 6.6 billion by 2025 from USD 5.0 billion in 2020, at a CAGR of 5.5% during the forecast period.”
Market growth is driven largely by the increasing pharmaceutical R&D activities, innovations in animal models, the development of exclusive in vivo toxicology tests, and the increasing demand for personalized medicine.

“By Product, the consumables accounted for the largest share of the in vivo toxicology market.”
The in vivo toxicology market is categorized into instruments and consumables. The consumables segment is further categorized into animal models and reagents & kits. Animal models is sub segmented into mice, rat and other animals. The consumables segment accounted for the largest share of the in vivo toxicology market in 2019. The widespread use of reagents & kits in research activities, increase in funds for research projects, and their extensive application in the in vivo toxicology studies are fueling the growth of this segment.

“By toxicity endpoint, the immunotoxicity segment accounted for the largest share of the in vivo toxicology market.”
The global in vivo toxicology market is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental & reproductive toxicity (DART), and other toxicity endpoints (includes organ toxicity, endocrine disruptor toxicity, juvenile toxicity, phototoxicity, ocular toxicity, and skin irritation). In 2019, the immunotoxicity segment accounted for the largest share of the global in vivo toxicology market, followed by the systemic toxicity segment.The rising demand for the development of biologics and biosimilars is driving the growth of the immunotoxicity segment

“By test type, chronic test type segment accounted for the largest share of the in vivo toxicology market”
The global in vivo toxicology market is segmented into acute, sub-acute, sub-chronic, and chronic test type. The chronic test type segment is expected to dominate the market during the forecast period. In 2019, the chronic test type segment held the largest share of the market, followed by sub-chronic test type.Increasing research on drugs used for longer-duration therapy such as anti-cancer, anti-convulsive, anti-arthritis, and anti-hypertensives drives the growth of the chronic test type market.

“By End user, Academic and Research Institutes accounted for the largest share of the in vivo toxicology market”
The global in vivo toxicology market has been broadly segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users (cosmetic companies and food laboratories). The academic and research institutes segment accounted for the largest share of the in vivo toxicology market in 2019. The increasing number of research activities in the field of in vivo toxicology and funding to the academic and research institutes to conduct in vivo toxicology research are the factors responsible for the largest share of the segment

“Asia Pacific: The fastest-growing region in the in vivo toxicology market.”
The Asia Pacific market is projected to grow at the highest CAGR during the forecast period. Several global pharmaceutical firms have entered the APAC market to tap the significant growth opportunities in emerging Asian countries and lower their production costs by shifting their drug discovery R&D operations and manufacturing to the region. A large number of qualified researchers and low-cost operations in APAC countries, such as India and China, are some of the major factors supporting this trend.

“North America: The largest share of the in vivo toxicology market.”
North America, which includes the US and Canada, accounted for the largest share of the in vivo toxicology market. The large share of the North America region can be attributed to the presence of major players operating in the in vivo toxicology market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.

Breakdown of primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:
• By Respondent– Supply Side- 80%, Demand Side-20%
• By Designation— Executives- 25%, CXOs- 20%, Managers – 55%
• By Region— North America – 50%, Europe – 20%, APAC – 20%, RoW- 10%

The in vivo toxicology market is dominated by a few globally established players such as Charles River Laboratories (US), The Jackson Laboratory (US), Envigo (US), Taconic Biosciences, Inc. (US), and JANVIER LABS (France), Thermo Fisher Scientific (US), Danaher Corporation (US), Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Bruker Corporation (US), PerkinElmer (US). Other prominent players include Merck KGaA (Germany), GE Healthcare (US), and Bio-Rad Laboratories (US), genOway (France), Cyagen Biosciences (US), GVK BIO (India), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioServices (France), Ozgene Pty Ltd. (Australia),and Harbour BioMed (US)

Research Coverage:
The report segments the in vivo toxicology market based on region (North America, Asia Pacific, Europe, Latin America and Middle East & Africa), product (instruments, consumables((Animal models (mice, rat and other animal odels), Reagents & kits)) test type (acute, sub-acute, sub-chronic, and chronic ) , Testing facility (outsourced and in-house), toxicity end point (immunotoxicity, systemic toxicity, carcinogenicity, end user(academic and research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users). Company type (Tier 1, tier 2, Tier 3 providers of in vivo toxicology instruments and services). The report also provides a comprehensive review of market drivers, challenges, and opportunities in the in vivo toxicology market.

Key Benefits of Buying the Report:
The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the in vivo toxicology market and provides them information on key market drivers, challenges, and opportunities.

【レポートの目次】

1 INTRODUCTION 38
1.1 OBJECTIVES OF THE STUDY 38
1.2 MARKET DEFINITION 38
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 38
1.3 MARKET SCOPE 39
1.3.1 MARKETS COVERED 39
FIGURE 1 IN VIVO TOXICOLOGY MARKET SEGMENTATION 39
1.3.2 YEARS CONSIDERED FOR THE STUDY 40
1.4 CURRENCY 40
1.5 LIMITATIONS 40
1.6 STAKEHOLDERS 40
1.7 SUMMARY OF CHANGES 41
2 RESEARCH METHODOLOGY 42
2.1 RESEARCH DATA 42
2.1.1 SECONDARY DATA 42
2.1.2 PRIMARY DATA 43
FIGURE 2 BREAKDOWN OF PRIMARIES: IN VIVO TOXICOLOGY MARKET 43
2.1.3 MARKET DATA ESTIMATION & TRIANGULATION 44
FIGURE 3 DATA TRIANGULATION METHODOLOGY 44
2.2 MARKET ESTIMATION METHODOLOGY 45
FIGURE 4 MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION) 45
FIGURE 5 IN VIVO TOXICOLOGY MARKET SIZE (USD MILLION) 45
FIGURE 6 IN VIVO TOXICOLOGY MARKET: GROWTH RATE OF TOP COMPANIES (2017−2019) 46
FIGURE 7 IN VIVO TOXICOLOGY MARKET: FINAL CAGR PROJECTIONS (2020−2025) 46
FIGURE 8 IN VIVO TOXICOLOGY MARKET: CAGR PROJECTIONS FROM THE ANALYSIS OF DEMAND-SIDE DRIVERS AND OPPORTUNITIES 47
2.3 INDUSTRY INSIGHTS 48
2.4 ASSUMPTIONS FOR THE STUDY 48
3 EXECUTIVE SUMMARY 49
FIGURE 9 IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION) 49
FIGURE 10 IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2020 VS. 2025 (USD MILLION) 50
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE IN VIVO TOXICOLOGY MARKET 51

4 PREMIUM INSIGHTS 52
4.1 IN VIVO TOXICOLOGY MARKET OVERVIEW 52
FIGURE 12 INCREASING PHARMACEUTICAL R&D ACTIVITIES TO DRIVE MARKET GROWTH 52
4.2 IN VIVO TOXICOLOGY MARKET SHARE, BY TOXICITY ENDPOINT, 2020 VS. 2025 52
FIGURE 13 IMMUNOTOXICITY SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2025 52
4.3 IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2020 VS. 2025 (USD MILLION) 53
FIGURE 14 OUTSOURCED TESTING FACILITIES SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD 53
4.4 IN VIVO TOXICOLOGY MARKET SHARE, BY END USER, 2020 VS. 2025 53
FIGURE 15 ACADEMIC & RESEARCH INSTITUTES ARE THE LARGEST END USERS OF IN VIVO TOXICOLOGY PRODUCTS 53
5 MARKET OVERVIEW 54
5.1 MARKET DYNAMICS 54
FIGURE 16 IN VIVO TOXICOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
5.1.1 DRIVERS 55
5.1.1.1 Increasing pharmaceutical R&D activities 55
TABLE 1 R&D INVESTMENTS OF NOTE 55
5.1.1.2 Innovations in animal models 56
TABLE 2 INNOVATIVE ANIMAL MODELS DEVELOPED AND LAUNCHED BY PLAYERS 56
5.1.1.3 Exclusive in vivo toxicology tests 56
5.1.1.4 Increasing demand for personalized medicine 57
5.1.2 RESTRAINTS 57
5.1.2.1 Alternatives to animal testing 57
5.1.3 OPPORTUNITIES 58
5.1.3.1 Rising demand for humanized animal models 58
5.1.4 CHALLENGES 58
5.1.4.1 Regulations and laws for the ethical use of animals in research 58
5.2 IMPACT OF COVID-19 ON THE VIVO TOXICOLOGY MARKET 59
5.3 REGULATORY ASSESSMENT 59
5.3.1 INTRODUCTION 59
5.3.2 NORTH AMERICA 59
5.3.3 EUROPE 60
5.3.4 CHINA 61
5.3.5 JAPAN 62
5.3.6 INDIA 62
5.3.7 AUSTRALIA 63
5.3.8 BRAZIL 63

5.4 PATENT ANALYSIS 64
5.4.1 TOP EIGHT INSTITUTES WITH THE HIGHEST NO. OF PATENT FILINGS FOR ANIMAL MODELS IN THE LAST 10 YEARS 64
5.4.2 TOP 20 ACTIVE COUNTRIES IN PATENT FILING (ANIMAL MODELS) IN THE LAST 10 YEARS 64
5.4.3 FIELD OF STUDY IN PATENT FILING (ANIMAL MODELS) IN THE LAST 10 YEARS 65
5.5 TRADE ANALYSIS 65
5.5.1 TRADE ANALYSIS FOR CHROMATOGRAPHY AND ELECTROPHORESIS INSTRUMENTS 65
TABLE 3 IMPORT DATA FOR ELECTROPHORESIS AND CHROMATOGRAPHY INSTRUMENTS, BY COUNTRY, 2016–2020 (USD THOUSAND) 66
5.5.2 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 67
TABLE 4 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016-2020 (USD THOUSAND) 67
5.6 PORTER’S FIVE FORCES ANALYSIS 68
TABLE 5 PORTER’S FIVE FORCES ANALYSIS 68
5.6.1 THREAT OF NEW ENTRANTS 68
5.6.2 THREAT OF SUBSTITUTES 68
5.6.3 BARGAINING POWER OF SUPPLIERS 69
5.6.4 BARGAINING POWER OF BUYERS 69
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 69
5.7 SUPPLY CHAIN ANALYSIS 69
FIGURE 17 DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES 70
5.7.1 KEY INFLUENCERS 70
5.8 VALUE CHAIN ANALYSIS 71
FIGURE 18 MAJOR VALUE IS ADDED DURING THE MANUFACTURING
AND ASSEMBLY PHASES 71
5.9 ECOSYSTEM ANALYSIS OF THE IN VIVO TOXICOLOGY MARKET 72
FIGURE 19 ECOSYSTEM ANALYSIS 72
6 IN VIVO TOXICOLOGY MARKET, BY PRODUCT 73
6.1 INTRODUCTION 74
TABLE 6 IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 74
6.2 CONSUMABLES 74
TABLE 7 IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE,
2018–2025 (USD MILLION) 74
TABLE 8 IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY REGION,
2018–2025 (USD MILLION) 75
TABLE 9 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES,
BY COUNTRY, 2018–2025 (USD MILLION) 75
TABLE 10 EUROPE: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY COUNTRY, 2018–2025 (USD MILLION) 75
TABLE 11 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES,
BY COUNTRY, 2018–2025 (USD MILLION) 76
TABLE 12 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES,
BY COUNTRY, 2018–2025 (USD MILLION) 76
6.2.1 REAGENTS & KITS 76
6.2.1.1 Reagents & kits hold the largest share of the consumables market 76
TABLE 13 IN VIVO TOXICOLOGY MARKET FOR REAGENTS & KITS, BY REGION,
2018–2025 (USD MILLION) 77
TABLE 14 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR REAGENTS & KITS,
BY COUNTRY, 2018–2025 (USD MILLION) 77
TABLE 15 EUROPE: IN VIVO TOXICOLOGY MARKET FOR REAGENTS & KITS, BY COUNTRY, 2018–2025 (USD MILLION) 77
TABLE 16 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR REAGENTS & KITS,
BY COUNTRY, 2018–2025 (USD MILLION) 78
TABLE 17 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR REAGENTS & KITS,
BY COUNTRY, 2018–2025 (USD MILLION) 78
6.2.2 ANIMAL MODELS 78
TABLE 18 IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2018–2025 (USD MILLION) 79
TABLE 19 IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY REGION,
2018–2025 (USD MILLION) 79
TABLE 20 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS,
BY COUNTRY, 2018–2025 (USD MILLION) 79
TABLE 21 EUROPE: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY COUNTRY, 2018–2025 (USD MILLION) 80
TABLE 22 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS,
BY COUNTRY, 2018–2025 (USD MILLION) 80
TABLE 23 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS,
BY COUNTRY, 2018–2025 (USD MILLION) 80
6.2.2.1 Mice models 81
6.2.2.1.1 Mice models are widely used in in vivo toxicity testing 81
TABLE 24 PROMINENT MICE MODELS AVAILABLE IN THE MARKET 81
TABLE 25 IN VIVO TOXICOLOGY MARKET FOR MICE MODELS, BY REGION,
2018–2025 (USD MILLION) 82
TABLE 26 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR MICE MODELS,
BY COUNTRY, 2018–2025 (USD MILLION) 82
TABLE 27 EUROPE: IN VIVO TOXICOLOGY MARKET FOR MICE MODELS, BY COUNTRY, 2018–2025 (USD MILLION) 82
TABLE 28 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR MICE MODELS,
BY COUNTRY, 2018–2025 (USD MILLION) 83
TABLE 29 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR MICE MODELS,
BY COUNTRY, 2018–2025 (USD MILLION) 83
6.2.2.2 Rat models 83
6.2.2.2.1 Ease of performing surgery on rat models and development of genetically modified rat models drive the market 83
TABLE 30 IN VIVO TOXICOLOGY MARKET FOR RAT MODELS, BY REGION,
2018–2025 (USD MILLION) 84
TABLE 31 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR RAT MODELS,
BY COUNTRY, 2018–2025 (USD MILLION) 84
TABLE 32 EUROPE: IN VIVO TOXICOLOGY MARKET FOR RAT MODELS, BY COUNTRY, 2018–2025 (USD MILLION) 85
TABLE 33 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR RAT MODELS, BY COUNTRY, 2018–2025 (USD MILLION) 85
TABLE 34 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR RAT MODELS,
BY COUNTRY, 2018–2025 (USD MILLION) 85
6.2.2.3 Other animal models 86
TABLE 35 GUINEA PIG AND HAMSTER MODELS: ADVANTAGES AND USAGE 86
TABLE 36 NON-RODENT ANIMAL MODELS: ADVANTAGES AND USAGE 87
TABLE 37 IN VIVO TOXICOLOGY MARKET FOR OTHER ANIMAL MODELS, BY REGION, 2018–2025 (USD MILLION) 87
TABLE 38 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR OTHER ANIMAL MODELS, BY COUNTRY, 2018–2025 (USD MILLION) 87
TABLE 39 EUROPE: IN VIVO TOXICOLOGY MARKET FOR OTHER ANIMAL MODELS,
BY COUNTRY, 2018–2025 (USD MILLION) 88
TABLE 40 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR OTHER ANIMAL MODELS, BY COUNTRY, 2018–2025 (USD MILLION) 88
TABLE 41 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR OTHER ANIMAL MODELS, BY COUNTRY, 2018–2025 (USD MILLION) 88
6.3 INSTRUMENTS 89
6.3.1 GROWING RESEARCH AND INTRODUCTION OF COMBINATION INSTRUMENTS ARE KEY GROWTH FACTORS 89
TABLE 42 IN VIVO TOXICOLOGY MARKET FOR INSTRUMENTS, BY REGION,
2018–2025 (USD MILLION) 89
TABLE 43 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR INSTRUMENTS,
BY COUNTRY, 2018–2025 (USD MILLION) 90
TABLE 44 EUROPE: IN VIVO TOXICOLOGY MARKET FOR INSTRUMENTS, BY COUNTRY, 2018–2025 (USD MILLION) 90
TABLE 45 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR INSTRUMENTS,
BY COUNTRY, 2018–2025 (USD MILLION) 90
TABLE 46 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR INSTRUMENTS,
BY COUNTRY, 2018–2025 (USD MILLION) 91
7 IN VIVO TOXICOLOGY MARKET, BY TEST TYPE 92
7.1 INTRODUCTION 93
TABLE 47 IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION) 93
7.2 CHRONIC TOXICITY TESTING 93
7.2.1 CHRONIC TOXICITY TESTING IS ESSENTIAL FOR NEW DRUG ENTITY APPROVALS 93
TABLE 48 CHRONIC TOXICITY TESTING MARKET, BY REGION,
2018–2025 (USD MILLION) 94
TABLE 49 NORTH AMERICA: CHRONIC TOXICITY TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 94
TABLE 50 EUROPE: CHRONIC TOXICITY TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 94
TABLE 51 ASIA PACIFIC: CHRONIC TOXICITY TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 95
TABLE 52 LATIN AMERICA: CHRONIC TOXICITY TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 95

7.3 SUB-CHRONIC TOXICITY TESTING 95
7.3.1 SUB-CHRONIC TOXICITY TESTS PROVIDE DATA ON MANY PARAMETERS OF CHRONIC TOXICITY 95
TABLE 53 SUB-CHRONIC TOXICITY TESTING MARKET, BY REGION, 2018–2025 (USD MILLION) 96
TABLE 54 NORTH AMERICA: SUB-CHRONIC TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 96
TABLE 55 EUROPE: SUB-CHRONIC TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 96
TABLE 56 ASIA PACIFIC: SUB-CHRONIC TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 97
TABLE 57 LATIN AMERICA: SUB-CHRONIC TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 97
7.4 SUB-ACUTE TOXICITY TESTING 97
7.4.1 LONG OBSERVATION REQUIREMENTS AND HIGH ANIMAL SAMPLE SIZES ARE CHALLENGES ASSOCIATED WITH SUB-ACUTE TESTING 97
TABLE 58 SUB-ACUTE TOXICITY TESTING MARKET, BY REGION, 2018–2025 (USD MILLION) 98
TABLE 59 NORTH AMERICA: SUB-ACUTE TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 98
TABLE 60 EUROPE: SUB-ACUTE TOXICITY TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 98
TABLE 61 ASIA PACIFIC: SUB-ACUTE TOXICITY TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 99
TABLE 62 LATIN AMERICA: SUB-ACUTE TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 99
7.5 ACUTE TOXICITY TESTING 99
7.5.1 DISADVANTAGES OF ACUTE TOXICITY TESTING HAVE DRIVEN USE OF ALTERNATIVES 99
TABLE 63 ALTERNATIVE METHODS TO DETERMINE LD50 IN ACUTE TOXICITY TESTING 100
TABLE 64 ACUTE TOXICITY TESTING MARKET, BY REGION, 2018–2025 (USD MILLION) 100
TABLE 65 NORTH AMERICA: ACUTE TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 100
TABLE 66 EUROPE: ACUTE TOXICITY TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 101
TABLE 67 ASIA PACIFIC: ACUTE TOXICITY TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 101
TABLE 68 LATIN AMERICA: ACUTE TOXICITY TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 101
8 IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY 102
8.1 INTRODUCTION 103
TABLE 69 IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 103
8.2 OUTSOURCED TESTING FACILITIES 103
8.2.1 FOCUS ON COST CURTAILMENT AND NEED TO ACCESS SKILLED LABOR & EXPERTISE HAS BOOSTED OUTSOURCING 103
TABLE 70 IN VIVO TOXICOLOGY MARKET FOR OUTSOURCED TESTING FACILITIES,
BY REGION, 2018–2025 (USD MILLION) 104
TABLE 71 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR OUTSOURCED TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION) 105
TABLE 72 EUROPE: IN VIVO TOXICOLOGY MARKET FOR OUTSOURCED TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION) 105
TABLE 73 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR OUTSOURCED TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION) 105
TABLE 74 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR OUTSOURCED TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION) 106
8.3 IN-HOUSE TESTING FACILITIES 106
8.3.1 HIGH COSTS OF IN-HOUSE TESTING RESTRICT MARKET GROWTH 106
TABLE 75 IN VIVO TOXICOLOGY MARKET FOR IN-HOUSE TESTING FACILITIES, BY REGION, 2018–2025 (USD MILLION) 106
TABLE 76 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR IN-HOUSE TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION) 107
TABLE 77 EUROPE: IN VIVO TOXICOLOGY MARKET FOR IN-HOUSE TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION) 107
TABLE 78 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR IN-HOUSE TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION) 107
TABLE 79 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR IN-HOUSE TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION) 108
9 IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT 109
9.1 INTRODUCTION 110
TABLE 80 IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 110
9.2 IMMUNOTOXICITY 110
9.2.1 IMMUNOTOXICITY TESTING HOLDS THE LARGEST SHARE OF THE MARKET,
BY ENDPOINT 110
TABLE 81 IN VIVO TOXICOLOGY MARKET FOR IMMUNOTOXICITY, BY REGION,
2018–2025 (USD MILLION) 111
TABLE 82 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR IMMUNOTOXICITY,
BY COUNTRY, 2018–2025 (USD MILLION) 111
TABLE 83 EUROPE: IN VIVO TOXICOLOGY MARKET FOR IMMUNOTOXICITY, BY COUNTRY, 2018–2025 (USD MILLION) 111
TABLE 84 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR IMMUNOTOXICITY,
BY COUNTRY, 2018–2025 (USD MILLION) 112
TABLE 85 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR IMMUNOTOXICITY,
BY COUNTRY, 2018–2025 (USD MILLION) 112
9.3 SYSTEMIC TOXICITY 112
9.3.1 SYSTEMIC TOXICITY HELPS IDENTIFY A RANGE OF PARAMETERS IN PHARMA/BIOLOGIC TESTING 112
TABLE 86 IN VIVO TOXICOLOGY MARKET FOR SYSTEMIC TOXICITY, BY REGION,
2018–2025 (USD MILLION) 113
TABLE 87 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR SYSTEMIC TOXICITY,
BY COUNTRY, 2018–2025 (USD MILLION) 113
TABLE 88 EUROPE: IN VIVO TOXICOLOGY MARKET FOR SYSTEMIC TOXICITY,
BY COUNTRY, 2018–2025 (USD MILLION) 113
TABLE 89 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR SYSTEMIC TOXICITY,
BY COUNTRY, 2018–2025 (USD MILLION) 114
TABLE 90 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR SYSTEMIC TOXICITY,
BY COUNTRY, 2018–2025 (USD MILLION) 114
9.4 CARCINOGENICITY 114
9.4.1 RISING CANCER RESEARCH IS DRIVING THE MARKET FOR CARCINOGENICITY TESTING 114
TABLE 91 IN VIVO TOXICOLOGY MARKET FOR CARCINOGENICITY, BY REGION,
2018–2025 (USD MILLION) 115
TABLE 92 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR CARCINOGENICITY,
BY COUNTRY, 2018–2025 (USD MILLION) 115
TABLE 93 EUROPE: IN VIVO TOXICOLOGY MARKET FOR CARCINOGENICITY,
BY COUNTRY, 2018–2025 (USD MILLION) 115
TABLE 94 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR CARCINOGENICITY,
BY COUNTRY, 2018–2025 (USD MILLION) 116
TABLE 95 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR CARCINOGENICITY,
BY COUNTRY, 2018–2025 (USD MILLION) 116
9.5 GENOTOXICITY 116
9.5.1 GENOTOXICITY TESTING HELPS ISOLATE MUTATIVE SUBSTANCES 116
TABLE 96 TYPES OF GENOTOXICITY TESTS 117
TABLE 97 IN VIVO TOXICOLOGY MARKET FOR GENOTOXICITY, BY REGION,
2018–2025 (USD MILLION) 117
TABLE 98 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR GENOTOXICITY,
BY COUNTRY, 2018–2025 (USD MILLION) 118
TABLE 99 EUROPE: IN VIVO TOXICOLOGY MARKET FOR GENOTOXICITY, BY COUNTRY, 2018–2025 (USD MILLION) 118
TABLE 100 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR GENOTOXICITY,
BY COUNTRY, 2018–2025 (USD MILLION) 118
TABLE 101 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR GENOTOXICITY,
BY COUNTRY, 2018–2025 (USD MILLION) 119
9.6 DEVELOPMENTAL & REPRODUCTIVE TOXICITY 119
9.6.1 RISING PREVALENCE OF SEXUAL HEALTH & DEVELOPMENTAL ABNORMALITIES DRIVE MARKET GROWTH 119
TABLE 102 IN VIVO TOXICOLOGY MARKET FOR DART, BY REGION,
2018–2025 (USD MILLION) 119
TABLE 103 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR DART, BY COUNTRY, 2018–2025 (USD MILLION) 120
TABLE 104 EUROPE: IN VIVO TOXICOLOGY MARKET FOR DART, BY COUNTRY,
2018–2025 (USD MILLION) 120
TABLE 105 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR DART, BY COUNTRY,
2018–2025 (USD MILLION) 120
TABLE 106 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR DART, BY COUNTRY, 2018–2025 (USD MILLION) 121
9.7 OTHER TOXICITY ENDPOINTS 121
TABLE 107 IN VIVO TOXICOLOGY MARKET FOR OTHER TOXICITY ENDPOINTS, BY REGION, 2018–2025 (USD MILLION) 121
TABLE 108 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR OTHER TOXICITY ENDPOINTS, BY COUNTRY, 2018–2025 (USD MILLION) 122
TABLE 109 EUROPE: IN VIVO TOXICOLOGY MARKET FOR OTHER TOXICITY ENDPOINTS,
BY COUNTRY, 2018–2025 (USD MILLION) 122
TABLE 110 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR OTHER TOXICITY ENDPOINTS, BY COUNTRY, 2018–2025 (USD MILLION) 122
TABLE 111 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR OTHER TOXICITY ENDPOINTS, BY COUNTRY, 2018–2025 (USD MILLION) 123
10 IN VIVO TOXICOLOGY MARKET, BY END USER 124
10.1 INTRODUCTION 125
TABLE 112 IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION) 125
10.2 ACADEMIC & RESEARCH INSTITUTES 125
10.2.1 GROWING PARTNERSHIPS AND HIGH USE OF INSTRUMENTS & CONSUMABLES DRIVE MARKET GROWTH 125
TABLE 113 IN VIVO TOXICOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2018–2025 (USD MILLION) 126
TABLE 114 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION) 126
TABLE 115 EUROPE: IN VIVO TOXICOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION) 126
TABLE 116 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION) 127
TABLE 117 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION) 127
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 127
10.3.1 GROWING IMPORTANCE OF PRECLINICAL TOXICOLOGY EVALUATION HAS INCREASED DEMAND FOR TESTING, ESPECIALLY IN PHARMA COMPANIES 127
TABLE 118 IN VIVO TOXICOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018–2025 (USD MILLION) 128
TABLE 119 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION) 128
TABLE 120 EUROPE: IN VIVO TOXICOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION) 129
TABLE 121 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION) 129
TABLE 122 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION) 129
10.4 CONTRACT RESEARCH ORGANIZATIONS 130
10.4.1 CONTRACT SERVICES HAVE REGISTERED RISING DEMAND DUE TO INCREASING COSTS OF RESEARCH 130
TABLE 123 IN VIVO TOXICOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018–2025 (USD MILLION) 130
TABLE 124 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 130
TABLE 125 EUROPE: IN VIVO TOXICOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 131
TABLE 126 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 131
TABLE 127 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 131
10.5 OTHER END USERS 132
TABLE 128 IN VIVO TOXICOLOGY MARKET FOR OTHER END USERS, BY REGION,
2018–2025 (USD MILLION) 132
TABLE 129 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR OTHER END USERS,
BY COUNTRY, 2018–2025 (USD MILLION) 133
TABLE 130 EUROPE: IN VIVO TOXICOLOGY MARKET FOR OTHER END USERS,
BY COUNTRY, 2018–2025 (USD MILLION) 133
TABLE 131 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR OTHER END USERS,
BY COUNTRY, 2018–2025 (USD MILLION) 133
TABLE 132 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR OTHER END USERS,
BY COUNTRY, 2018–2025 (USD MILLION) 134

11 IN VIVO TOXICOLOGY MARKET, BY REGION 135
11.1 INTRODUCTION 136
FIGURE 20 IN VIVO TOXICOLOGY MARKET SNAPSHOT 136
TABLE 133 IN VIVO TOXICOLOGY MARKET, BY REGION, 2018–2025 (USD MILLION) 136
11.2 NORTH AMERICA 137
FIGURE 21 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET SNAPSHOT 137
TABLE 134 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 138
TABLE 135 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 138
TABLE 136 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES,
BY TYPE, 2018–2025 (USD MILLION) 138
TABLE 137 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS,
BY TYPE, 2018–2025 (USD MILLION) 139
TABLE 138 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 139
TABLE 139 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION) 139
TABLE 140 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION) 140
TABLE 141 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 140
11.2.1 US 140
11.2.1.1 Government funding for life sciences research drives the market growth in the US 140
TABLE 142 US: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 141
TABLE 143 US: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE,
2018–2025 (USD MILLION) 141
TABLE 144 US: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2018–2025 (USD MILLION) 142
TABLE 145 US: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION) 142
TABLE 146 US: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 142
TABLE 147 US: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 143
TABLE 148 US: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 143
11.2.2 CANADA 143
11.2.2.1 Growth in stem cell research activities expected to lead to market expansion 143
TABLE 149 CANADA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 144
TABLE 150 CANADA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION) 144
TABLE 151 CANADA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION) 144
TABLE 152 CANADA: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 145
TABLE 153 CANADA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 145
TABLE 154 CANADA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 145
TABLE 155 CANADA: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 146
11.3 EUROPE 146
TABLE 156 EUROPE: IN VIVO TOXICOLOGY MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 146
TABLE 157 EUROPE: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 147
TABLE 158 EUROPE: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION) 147
TABLE 159 EUROPE: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION) 147
TABLE 160 EUROPE: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 148
TABLE 161 EUROPE: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 148
TABLE 162 EUROPE: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 148
TABLE 163 EUROPE: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 149
11.3.1 UK 149
11.3.1.1 Increasing focus on cancer research in the UK is a key market growth driver 149
TABLE 164 UK: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 149
TABLE 165 UK: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE,
2018–2025 (USD MILLION) 150
TABLE 166 UK: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2018–2025 (USD MILLION) 150
TABLE 167 UK: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION) 150
TABLE 168 UK: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 151
TABLE 169 UK: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 151
TABLE 170 UK: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 151
11.3.2 GERMANY 152
11.3.2.1 Germany accounted for the second-largest share of the European market 152
TABLE 171 GERMANY: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 152
TABLE 172 GERMANY: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION) 152
TABLE 173 GERMANY: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION) 153
TABLE 174 GERMANY: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 153
TABLE 175 GERMANY: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 153
TABLE 176 GERMANY: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 154
TABLE 177 GERMANY: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 154
11.3.3 FRANCE 154
11.3.3.1 Increased investments in proteomics and genomics to fuel growth of mice models 154
TABLE 178 FRANCE: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 155
TABLE 179 FRANCE: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION) 155
TABLE 180 FRANCE: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION) 155
TABLE 181 FRANCE: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 156
TABLE 182 FRANCE: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 156
TABLE 183 FRANCE: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 156
TABLE 184 FRANCE: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 157
11.3.4 ITALY 157
11.3.4.1 Growth in the biotechnology and pharmaceutical industries to drive market growth 157
TABLE 185 ITALY: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 157
TABLE 186 ITALY: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE,
2018–2025 (USD MILLION) 158
TABLE 187 ITALY: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2018–2025 (USD MILLION) 158
TABLE 188 ITALY: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 158
TABLE 189 ITALY: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 159
TABLE 190 ITALY: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 159
TABLE 191 ITALY: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 159
11.3.5 SPAIN 160
11.3.5.1 Short study start-up times and rising R&D expenditure to boost the growth of the Spanish market 160
TABLE 192 SPAIN: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 160
TABLE 193 SPAIN: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE,
2018–2025 (USD MILLION) 160
TABLE 194 SPAIN: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2018–2025 (USD MILLION) 161
TABLE 195 SPAIN: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 161
TABLE 196 SPAIN: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 161
TABLE 197 SPAIN: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 162
TABLE 198 SPAIN: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 162
11.3.6 REST OF EUROPE 162
TABLE 199 ROE: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 163
TABLE 200 ROE: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES,
BY TYPE, 2018–2025 (USD MILLION) 163
TABLE 201 ROE: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS,
BY TYPE, 2018–2025 (USD MILLION) 163
TABLE 202 ROE: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 164
TABLE 203 ROE: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 164
TABLE 204 ROE: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 164
TABLE 205 ROE: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 165
11.4 ASIA PACIFIC 165
FIGURE 22 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET SNAPSHOT 166
TABLE 206 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 167
TABLE 207 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 167
TABLE 208 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION) 167
TABLE 209 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION) 168
TABLE 210 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 168
TABLE 211 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 168
TABLE 212 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 169
TABLE 213 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 169
11.4.1 CHINA 169
11.4.1.1 International alliances for R&D are driving the market 169
TABLE 214 CHINA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 170
TABLE 215 CHINA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE,
2018–2025 (USD MILLION) 170
TABLE 216 CHINA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2018–2025 (USD MILLION) 170
TABLE 217 CHINA: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 171
TABLE 218 CHINA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 171
TABLE 219 CHINA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 171
TABLE 220 CHINA: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 172
11.4.2 JAPAN 172
11.4.2.1 Increasing focus on personalized diagnostics products to support market growth 172
TABLE 221 JAPAN: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 172
TABLE 222 JAPAN: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE,
2018–2025 (USD MILLION) 173
TABLE 223 JAPAN: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2018–2025 (USD MILLION) 173
TABLE 224 JAPAN: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 173
TABLE 225 JAPAN: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 174
TABLE 226 JAPAN: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 174
TABLE 227 JAPAN: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 174
11.4.3 INDIA 175
11.4.3.1 Robust growth in the biotech industry in India to boost the market growth 175
TABLE 228 INDIA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 175
TABLE 229 INDIA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE,
2018–2025 (USD MILLION) 175
TABLE 230 INDIA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2018–2025 (USD MILLION) 176
TABLE 231 INDIA: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 176
TABLE 232 INDIA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 176
TABLE 233 INDIA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 177
TABLE 234 INDIA: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 177
11.4.4 REST OF ASIA PACIFIC 177
TABLE 235 ROAPAC: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 178
TABLE 236 ROAPAC: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION) 178
TABLE 237 ROAPAC: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION) 178
TABLE 238 ROAPAC: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 179
TABLE 239 ROAPAC: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 179
TABLE 240 ROAPAC: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 179
TABLE 241 ROAPAC: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 180
11.5 LATIN AMERICA 180
TABLE 242 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 180
TABLE 243 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 181
TABLE 244 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION) 181
TABLE 245 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS,
BY TYPE, 2018–2025 (USD MILLION) 181
TABLE 246 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 182
TABLE 247 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION) 182
TABLE 248 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 182
TABLE 249 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 183
11.5.1 BRAZIL 183
11.5.1.1 Growing biologics sector in the country to drive the market 183
TABLE 250 BRAZIL: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 183
TABLE 251 BRAZIL: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE,
2018–2025 (USD MILLION) 184
TABLE 252 BRAZIL: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION) 184
TABLE 253 BRAZIL: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 184
TABLE 254 BRAZIL: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 185
TABLE 255 BRAZIL: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 185
TABLE 256 BRAZIL: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 185
11.5.2 MEXICO 186
11.5.2.1 Favorable business environment for market players to support market growth 186
TABLE 257 MEXICO: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 186
TABLE 258 MEXICO: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE,
2018–2025 (USD MILLION) 186
TABLE 259 MEXICO: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION) 187
TABLE 260 MEXICO: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 187
TABLE 261 MEXICO: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 187
TABLE 262 MEXICO: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 188
TABLE 263 MEXICO: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 188
11.5.3 REST OF LATIN AMERICA 188
TABLE 264 ROLATAM: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 188
TABLE 265 ROLATAM: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION) 189
TABLE 266 ROLATAM: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION) 189
TABLE 267 ROLATAM: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 189
TABLE 268 ROLATAM: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2018–2025 (USD MILLION) 190
TABLE 269 ROLATAM: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2018–2025 (USD MILLION) 190
TABLE 270 ROLATAM: IN VIVO TOXICOLOGY MARKET, BY END USER,
2018–2025 (USD MILLION) 190
11.6 MIDDLE EAST & AFRICA 191
11.6.1 INFRASTRUCTURAL DEVELOPMENT TO CONTRIBUTE TO MARKET GROWTH IN THE MEA 191
TABLE 271 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 191
TABLE 272 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION) 191
TABLE 273 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION) 192
TABLE 274 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE,
2018–2025 (USD MILLION) 192
TABLE 275 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION) 193
TABLE 276 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION) 193
TABLE 277 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION) 193
12 COMPETITIVE LANDSCAPE 194
12.1 INTRODUCTION 194
12.2 MARKET SHARE ANALYSIS (2019) 194
FIGURE 23 IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY KEY PLAYER, 2019 194
12.2.1 ENVIGO (US) 195
12.3 MARKET RANKING ANALYSIS 196
FIGURE 24 COMPANY RANKING IN THE IN VIVO TOXICOLOGY INSTRUMENTS MARKET, 2019 196
12.4 MARKET EVALUATION FRAMEWORK (ANIMAL MODELS) 197
TABLE 278 MARKET EVALUATION FRAMEWORK: PRODUCT LAUNCHES WAS THE MAJOR STRATEGY ADOPTED BY PLAYERS 197
12.5 COMPETITIVE SCENARIO 197
12.5.1 KEY PRODUCT LAUNCHES 197
12.5.2 KEY ACQUISITIONS 198
12.5.3 KEY COLLABORATIONS 198
12.5.4 KEY EXPANSIONS 198
12.6 MARKET EVALUATION FRAMEWORK (INSTRUMENTS) 199
12.6.1 KEY MARKET DEVELOPMENTS 199
12.6.1.1 Product launches 199
12.6.1.2 Acquisitions 199
12.6.1.3 Partnerships, collaborations, and agreements 200
12.6.1.4 Expansions 200
12.7 COMPANY PRODUCT FOOTPRINT 201
TABLE 279 PRODUCT PORTFOLIO ANALYSIS: IN VIVO TOXICOLOGY MARKET (ANIMAL MODELS) 201
12.8 COMPANY GEOGRAPHIC FOOTPRINT 202
TABLE 280 GEOGRAPHIC REVENUE MIX: IN VIVO TOXICOLOGY MARKET (2019) 202
12.9 REVENUE ANALYSIS OF KEY MARKET PLAYERS 203
FIGURE 25 REVENUE ANALYSIS: IN VIVO TOXICOLOGY MARKET (2019) 203

12.10 COMPETITIVE LEADERSHIP MAPPING: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS 204
12.10.1 STARS 204
12.10.2 EMERGING LEADERS 204
12.10.3 PERVASIVE PLAYERS 204
12.10.4 PARTICIPANTS 205
FIGURE 26 IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS: COMPANY EVALUATION MATRIX, 2019 205
12.11 COMPETITIVE LEADERSHIP MAPPING: IN VIVO TOXICOLOGY MARKET FOR INSTRUMENTS 206
12.11.1 STARS 206
12.11.2 EMERGING LEADERS 206
12.11.3 PERVASIVE PLAYERS 206
12.11.4 PARTICIPANTS 206
FIGURE 27 IN VIVO TOXICOLOGY MARKET FOR INSTRUMENTS: COMPANY EVALUATION MATRIX, 2019 207
13 COMPANY PROFILES 208
13.1 MAJOR PLAYERS 208
(Business Overview, Products Offered, Recent Developments, MnM View)*
13.1.1 CHARLES RIVER LABORATORIES 208
TABLE 281 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 208
FIGURE 28 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2019) 209
13.1.2 THE JACKSON LABORATORY 212
TABLE 282 THE JACKSON LABORATORY: BUSINESS OVERVIEW 212
FIGURE 29 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2019) 212
13.1.3 ENVIGO 215
TABLE 283 ENVIGO: BUSINESS OVERVIEW 215
13.1.4 TACONIC BIOSCIENCES 218
TABLE 284 TACONIC BIOSCIENCES, INC.: BUSINESS OVERVIEW 218
13.1.5 GENOWAY 221
TABLE 285 GENOWAY: BUSINESS OVERVIEW 221
FIGURE 30 GENOWAY: COMPANY SNAPSHOT (2019) 221
13.1.6 HARBOUR BIOMED 224
TABLE 286 HARBOUR BIOMED: BUSINESS OVERVIEW 224
13.1.7 CROWN BIOSCIENCE 225
TABLE 287 CROWN BIOSCIENCE, INC.: BUSINESS OVERVIEW 225
13.1.8 TRANSCURE BIOSERVICES 228
TABLE 288 TRANSCURE BIOSERVICES: BUSINESS OVERVIEW 228
13.1.9 OZGENE PTY LTD. 229
TABLE 289 OZGENE PTY LTD.: BUSINESS OVERVIEW 229
13.1.10 THERMO FISHER SCIENTIFIC 230
TABLE 290 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 230
FIGURE 31 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2019) 231
13.1.11 DANAHER CORPORATION 236
TABLE 291 DANAHER CORPORATION: BUSINESS OVERVIEW 236
FIGURE 32 DANAHER CORPORATION: COMPANY SNAPSHOT (2019) 236
13.1.12 AGILENT TECHNOLOGIES 239
TABLE 292 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW 239
FIGURE 33 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2019) 239
13.1.13 WATERS CORPORATION 243
TABLE 293 WATERS CORPORATION: BUSINESS OVERVIEW 243
FIGURE 34 WATERS CORPORATION: COMPANY SNAPSHOT (2019) 243
13.1.14 SHIMADZU CORPORATION 246
TABLE 294 SHIMADZU CORPORATION: BUSINESS OVERVIEW 246
FIGURE 35 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2019) 246
13.1.15 BIO-RAD LABORATORIES 249
TABLE 295 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 249
FIGURE 36 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2019) 250
13.1.16 BRUKER CORPORATION 251
TABLE 296 BRUKER CORPORATION: BUSINESS OVERVIEW 251
FIGURE 37 BRUKER CORPORATION: COMPANY SNAPSHOT (2019) 251
13.1.17 PERKINELMER 253
TABLE 297 PERKINELMER, INC.: BUSINESS OVERVIEW 253
FIGURE 38 PERKINELMER, INC.: COMPANY SNAPSHOT (2019) 253
13.2 OTHER PLAYERS 256
13.2.1 MERCK KGAA 256
TABLE 298 MERCK KGAA: BUSINESS OVERVIEW 256
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT (2019) 256
13.2.2 GE HEALTHCARE 258
TABLE 299 GE HEALTHCARE: BUSINESS OVERVIEW 258
FIGURE 40 GE HEALTHCARE: COMPANY SNAPSHOT (2019) 258
13.2.3 JANVIER LABS 260
TABLE 300 JANVIER LABS: BUSINESS OVERVIEW 260
13.2.4 INGENIOUS TARGETING LABORATORY 261
TABLE 301 INGENIOUS TARGETING LABORATORY: BUSINESS OVERVIEW 261
13.2.5 POLYGENE 263
TABLE 302 POLYGENE: BUSINESS OVERVIEW 263
13.2.6 GVK BIO 264
TABLE 303 GVK BIO: BUSINESS OVERVIEW 264
13.2.7 CYAGEN BIOSCIENCES 266
TABLE 304 CYAGEN BIOSCIENCES: BUSINESS OVERVIEW 266
13.2.8 DATA SCIENCES INTERNATIONAL 267
TABLE 305 DATA SCIENCE INTERNATIONAL: BUSINESS OVERVIEW 267
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
14 APPENDIX 269
14.1 DISCUSSION GUIDE 269
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 273
14.3 RELATED REPORTS 275
14.4 AUTHOR DETAILS 276

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のIn Vivo毒性試験市場予測:製品別、試験タイプ別、毒性指標別、試験施設別、エンドユーザー別(In Vivo Toxicology Market by Product (Animal Models, Reagents & Kits), Test Type (Chronic, Sub-acute), Toxicity Endpoints (Systemic, Immunotoxicity), Testing Facility (Outsourced, In-house), End User (Academic & Research Institute, CROs) - Forecast to 2025)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆